European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

Hermans, C; Giangrande, P L F; O'Mahony, B; de Kleijn, P; Bedford, M; Batorova, A; Blatný, J; Jansone, K

Hermans, C; Giangrande, P L F; O'Mahony, B; de Kleijn, P; Bedford, M; Batorova, A; Blatný, J; Jansone, K.

Afiliación

Hermans C; Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium. cedric.hermans@uclouvain.be.
Giangrande PLF; European Haemophilia Consortium, Brussels, Belgium.
O'Mahony B; University of Oxford, Oxford, UK.
de Kleijn P; European Haemophilia Consortium, Brussels, Belgium.
Bedford M; Trinity College, Dublin, Ireland.
Batorova A; Department of Rehabilitation, Nursing Science and Sports, University Medical Center Utrecht, Utrecht, the Netherlands.
Blatný J; Canterbury Christ Church University, Kent, UK.
Jansone K; National Hemophilia Center, Dept. of Hematology and Transfusion Medicine, School of Medicine of Comenius University and University Hospital, Bratislava, Slovakia.

Orphanet J Rare Dis ; 15(1): 219, 2020 08 24.

Article en En | MEDLINE | ID: mdl-32831110

Asunto(s)

Hemofilia A; Medicina; Trastornos de los Cromosomas Sexuales; Factor IX; Factor VIII; Hemofilia A/tratamiento farmacológico; Humanos

Palabras clave

Bypassing agents; Emicizumab; Factor IX; Factor VIII; Guidelines; Haemophilia; Immune tolerance; Inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos de los Cromosomas Sexuales / Hemofilia A / Medicina Límite: Humans Idioma: En Revista: Orphanet J Rare Dis Asunto de la revista: MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google